biohaven

Biohaven Ltd. is a biopharmaceutical company dedicated to discovering, developing, and commercializing transformative treatments in neuroscience, immunology, and oncology. With a patient-centric approach, Biohaven aims to address unmet medical needs by leveraging cutting-edge science and innovative technologies. The company's mission is to improve the lives of patients by delivering life-changing therapies, particularly for diseases with limited or no treatment options.

Key Strategic Focus

Biohaven's strategic focus encompasses several core objectives:

• Innovative Drug Development: Advancing a diverse pipeline of therapies targeting neurological and neuropsychiatric disorders, including rare diseases.

• Proprietary Platforms: Utilizing five proprietary drug development platforms to generate novel treatments efficiently.

• Digital Transformation: Implementing agile, tech-savvy operational models to enhance patient engagement and streamline drug development processes.

• Strategic Collaborations: Partnering with leading global companies and institutions to enhance research and development capabilities.

Financials and Funding

As of January 2022, Biohaven's valuation was estimated at $8 billion, with total funding of approximately $443.7 million. The company reported an estimated annual revenue of $307.6 million, with a revenue per employee of $590.4K. Biohaven's funding history includes strategic collaborations and licensing agreements with notable investors and partners such as Pfizer, Bristol-Myers Squibb, and Yale University.

Pipeline Development

Biohaven is advancing an extensive portfolio of late- and early-stage programs across 20 therapeutic indications in neuroscience, immunology, and oncology. Key pipeline candidates include:

• Troriluzole: In Phase 3 trials for neurological and neuropsychiatric illnesses.

• Taldefgrobep Alfa: In Phase 3 clinical trials for spinal muscular atrophy and obesity.

• BHV-7000: In Phase 3 clinical trials for focal and generalized epilepsy, and major depressive disorder.

• BHV-2100: In Phase 2 clinical trials for migraines and pain disorders.

• BHV-1510: In Phase 1/2 trials targeting advanced or metastatic epithelial tumors.

• BHV-8000: Completed Phase 1 clinical trials for Alzheimer's and Parkinson’s disease, and multiple sclerosis.

Technological Platform and Innovation

Biohaven's innovation is driven by its five proprietary drug development platforms, enabling rapid generation of novel therapies. The company's approach includes:

• Proprietary Technologies: Development of unique drug formulations with improved efficacy and mechanisms of action.

• Scientific Methodologies: Utilization of advanced scientific methods, including assays and machine learning algorithms, to enhance drug discovery and development.

• AI-Driven Capabilities: Integration of digital tools and technologies to increase engagement and enhance the success of novel treatments.

Leadership Team

Biohaven's leadership comprises experienced professionals with extensive backgrounds in drug development and commercialization:

• Vlad Coric, M.D.: Chairman & Chief Executive Officer. Dr. Coric has led Biohaven from a startup to a publicly traded company, overseeing the FDA approval and launch of Nurtec® ODT.

• Gregory H. Bailey, M.D.: Director. Dr. Bailey has over 15 years of experience as an entrepreneur and financier in the healthcare sector.

• John W. Childs: Director. Mr. Childs is the Chairman and Partner of J.W. Childs Associates, L.P., a private equity firm.

• Julia P. Gregory, MBA: Director. Ms. Gregory has extensive experience in the biopharmaceutical industry, having served as President and CEO of Five Prime Therapeutics, Inc.

• Michael T. Heffernan: Director. Mr. Heffernan is a seasoned biopharmaceutical leader with over 25 years of commercial experience.

• Douglas Gray Esq.: Corporate Secretary. Mr. Gray is a partner at Locke Lord LLP and co-chair of the firm’s Life Science Practice Group.

• Irina A. Antonijevic, M.D., Ph.D.: Director. Dr. Antonijevic has over 20 years of experience in drug development, focusing on neurologic and psychiatric disorders.

• Robert J. Hugin: Director. Mr. Hugin was instrumental in the strategic growth and global expansion of Celgene during his 19-year tenure.

• Kishen Mehta: Director. Mr. Mehta has over 15 years of experience in the financial industry and is currently Chief Investment Officer at Suvretta Capital Management, LLC.

Leadership Changes

In August 2022, Dr. Bruce D. Car joined Biohaven as Chief Scientific Officer, bringing over 25 years of experience from Bristol-Myers Squibb and Agios Pharmaceuticals.

Competitor Profile

Market Insights and Dynamics

The biopharmaceutical industry, particularly in the neurological disorders segment, is highly competitive and rapidly evolving. The global market for neurological disorder treatments is projected to grow significantly, driven by increasing prevalence and advancements in therapeutic options.

Competitor Analysis

Biohaven faces competition from both established pharmaceutical companies and emerging biotech firms:

• Amgen: Offers Aimovig (erenumab) for migraine treatment.

• Eli Lilly: Provides Emgality (galcanezumab) targeting migraine.

• Teva Pharmaceutical Industries: Markets Ajovy (fremanezumab) for migraine management.

• AbbVie: Through its acquisition of Allergan, offers Botox for chronic migraine.

• TG Therapeutics: Focuses on developing treatments for B-cell diseases, posing competition in the immunology space.

Strategic Collaborations and Partnerships

Biohaven has established significant collaborations to enhance its market position and innovation capacity:

• Pfizer: Entered a strategic commercialization arrangement for rimegepant in markets outside the United States.

• Merus N.V.: Collaborated to develop antibody-drug conjugates for cancer treatment.

• Yale University and Massachusetts General Hospital: Licensed intellectual property related to glutamate modulating agents.

Operational Insights

Biohaven's non-hierarchical, entrepreneurial structure enables rapid decision-making and innovation. The company's focus on digital transformation and patient-centric approaches differentiates it from competitors, allowing for efficient clinical execution and commercialization.

Strategic Opportunities and Future Directions

Biohaven aims to expand its product pipeline by developing treatments for other neurological disorders, such as Alzheimer's disease and multiple sclerosis. The company seeks to leverage strategic partnerships to enhance R&D capabilities and market outreach. With a growing demand for migraine treatments, Biohaven is well-positioned to capitalize on this favorable market environment.

Contact Information

For more information, visit Biohaven's official website.

Follow Biohaven on social media:

• Twitter: biohavenpharma

• LinkedIn: biohaven-pharmaceuticals